Global Acute Myeloid Leukemia (AML) Therapeutics Market to Reach $976.2 Billion by 2026

Abstract: Global Acute Myeloid Leukemia (AML) Therapeutics Market to Reach $976. 2 Billion by 2026 . Leukemias are malignant disorders, the main symptom of which is an abnormally high leucocyte count in the human bone marrow and/or blood.

New York, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Acute Myeloid Leukemia (AML) Therapeutics Industry" - https://www.reportlinker.com/p06051402/?utm_source=GNW
The disease causes a substantial number of deaths worldwide every year. The types of Leukaemia vary by origin, pathogenesis, prognosis, and incidence. The dominant leukemia cells may be mature cells like in chronic lymphocytic leukemia (CLL); acute leukemias with precursor cells of multiple lineages; or both mature and precursor cells like in chronic myeloid leukemia (CML). Among the severe types of leukemia, acute lymphoblastic leukemia (ALL) is often seen in children as also in young adults, particularly in the 2 to 5 years age groups, whereas acute myeloid leukemia (AML) is more commonly seen in adults. Additionally, other rare leukemia types like atypical chronic myeloid leukemia differ from the four major types in numerous respects.

Leukaemia incidences vary among patients of different sexes, ages and races and these disparities are associated primarily with levels of environmental exposure as also genetic factors. For instance, nearly 10% of patients developing CLL have a history of the ailment in the family. Similarly, ionizing radiation has been identified as a definite cause for ALL in children, and usually happens by way of X-ray pelvimetry done during a pregnancy. Due to previous initiatives taken for combating leukemia, the disease`s epidemiology can change with time, varying from nation to nation. Hence, being aware of leukemia`s upgraded epidemiological data and analyzing the ailment`s temporal trends are vital to learn about its burden and also to assess the overall effectiveness of prevention strategies adopted previously.

Amid the COVID-19 crisis, the global market for Acute Myeloid Leukemia (AML) Therapeutics estimated at US$476.9 Million in the year 2020, is projected to reach a revised size of US$976.2 Billion by 2026, growing at a CAGR of 12.6% over the analysis period. Cytarabine, one of the segments analyzed in the report, is projected to grow at a 15.1% CAGR to reach US$366.4 Million by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Anthracycline Drugs segment is readjusted to a revised 13.9% CAGR for the next 7-year period. This segment currently accounts for a 18.2% share of the global Acute Myeloid Leukemia (AML) Therapeutics market.

The U.S. Market is Estimated at $194.4 Million in 2021, While China is Forecast to Reach $85.7 Million by 2026

The Acute Myeloid Leukemia (AML) Therapeutics market in the U.S. is estimated at US$194.4 Million in the year 2021. The country currently accounts for a 37.19% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$85.7 Million in the year 2026 trailing a CAGR of 14.9% through the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 11% and 11.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 12.1% CAGR while Rest of European market (as defined in the study) will reach US$97 Million by the close of the analysis period.

The market is set to experience a lucrative growth over the coming years on account of confluence of various factors like rising prevalence of the medical condition and its relapse cases along with increasing focus on development of novel therapies. Increasing cases of acute myeloid leukemia can be credited to several factors like unhealthy lifestyles, genetic mutations, radiation exposure and extended exposure to certain toxic chemicals like benzene. There were around 61,780 new cases of leukemia and 22,840 mortalities in 2019 in the US. The number of acute myeloid leukemia cases was estimated at 21,450, with adults accounting for a major fraction of the patient population. The increasing prevalence along with high mortality rate in the US and other countries is paving way for higher uptake of associated therapies. The market growth is also favored by rising aging population and unmet healthcare needs. Moreover, the market expansion is favored by various benefits of biopharmaceuticals over traditional drugs, an impressive biopharmaceutical pipeline and continuing development of several combination therapies capable of treating challenging medical conditions.

The market is also slated to gain from ongoing advancements in molecular biology and pharmacology for development of novel drugs. Pharmaceutical players operating on the market are making significant investments in research projects to come up with novel options. These R&D endeavors are also attributed to limitations associated with existing therapies available on the market for acute myeloid leukemia. Traditional options for the medical condition are unable to control relapse and linked with various side-effects such as tissue damage, nausea and loss of appetite. These issues are driving companies to focus on advanced approaches such as serine-threonine protein kinases, stem cell transplant and pipeline drugs. The market growth is bound to be facilitated by upcoming therapies such as farnesyltransferase inhibitors, alkylating agents, immunotoxins, FMS-like tyrosine kinase 3 inhibitors, monoclonal antibodies and multi-drug-resistant modulators. These therapies are anticipated to gain acceptance owing to their enhanced survival rates, quality and safety.

Tyrosine Kinase Inhibitors Segment to Reach $114.9 Million by 2026

In the global Tyrosine Kinase Inhibitors segment, USA, Canada, Japan, China and Europe will drive the 10.1% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$52.6 Million in the year 2020 will reach a projected size of US$103.2 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$8.9 Million by the year 2026.
Select Competitors (Total 67 Featured)

• AbbVie Inc.

• Agios Pharmaceuticals, Inc.

• Amgen Inc.

• Astellas Pharma Inc.

• Astex Pharmaceuticals, Inc.

• Celgene Corporation

• CTI BioPharma Corp.

• Cyclacel Pharmaceuticals, Inc.

• Daiichi Sankyo Company Limited

• F. Hoffmann-La Roche AG

• Immune Pharmaceuticals Inc.

• Janssen-Cilag Limited

• Jazz Pharmaceuticals plc

• MEI Pharma, Inc.

• Novartis AG

• Pfizer Inc.

• Seattle Genetics, Inc.

• Stemline Therapeutics, Inc.

• Sunesis Pharmaceuticals, Inc.

• Tolero Pharmaceuticals, Inc.

Read the full report: https://www.reportlinker.com/p06051402/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
LEUKEMIA - A DISEASE OF THE BONE MARROW
A Prelude to Acute Myeloid Leukaemia (AML)
Acute Myeloid Leukaemia: Epidemiology
Acute Myeloid Leukaemia (AML) Types
The FAB Classification of AML
WHO AML Classification
Etiology of AML
AML Symptoms
COVID-19 IMPACT AND THE LOOMING RECESSION
COVID-19?s Impact on Cancer Patients
Making the Cancer Patient Survive the Lethal Covid-19 Wave
Post-Covid-19 Complications to Affect Future Cancer Treatment
The Evolving Model of Care - Virtual/ Telemedicine Consultations
The Evolving Model of Care - Extending Care through Innovative
Means
Pandemic Causes Delays in Procedures and Treatment
In-Office Cancer Patient Visits Decline as Pandemic Fear Escalates
Vaccine Availability Comforts Cancer Patients
COVID-19 IMPACT ON ACUTE MYELOID LEUKEMIA THERAPEUTICS
Pandemic Caused Delays Impact AML Patients
Pandemic Related Issues Affect Oncology Research
GLOBAL MARKET OUTLOOK AND PROSPECTS
Acute Myeloid Leukaemia (AML) Therapeutics Market Primed for
Massive Growth with Rising Patient Count & Promising Research
Efforts
Drug Development Efforts Set Pace for Global Market
RECENT LAUNCHES IN THE AML MARKET
North America Maintains Leadership Position in Global Market
Chemotherapy: The Standard Mode of Treatment for AML Over the
Years
Emerging Drug Therapies/Targeted Therapies for Acute Myeloid
Leukaemia to Drive Future Growth
FLT3 Inhibitors & Cytarabine: Bright Segments of Acute Myeloid
Leukaemia Therapeutics Market
EXISTING & POTENTIAL TREATMENT/THERAPEUTIC TARGETS FOR ACUTE
MYELOID LEUKEMIA
Chemotherapy
AML Treatment
Stem Cell Transplant for Acute Myeloid Leukaemia (AML)
Targeted Therapies Drive the Future of AML Market
EXHIBIT 1: Targeted Therapies Market for AML by Product Class:
Market Size Estimates in USD Million for 2020
EXHIBIT 2: Targeted Therapies Market for AML (2020) by Leading
Drugs: Market Share of Revenues
ISOCITRATE DEHYDROGENASES (IDH)
BCL-2 Inhibitor
FLT3
Hedgehog (Hh)
Immunotherapy-Oriented Treatments
Neurotransmitter Receptors
Epigenetic Modulators
Organelle-Directed Strategies
New Formulations Using Existing Options
Antibody-Drug Conjugate Therapy for Acute Leukaemia
RECENT MARKET ACTIVITY

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS
Ballooning Elderly Population: The Vital Growth Driver for AML
Therapeutics
EXHIBIT 3: Expanding Elderly Population Worldwide: Breakdown of
Number of People Aged 65+ Years in Million by Geographic
Region for the Years 2019 and 2030
EXHIBIT 4: Life Expectancy for Select Countries in Number of
Years: 2019
Advancements in Pharmacology & Molecular Biology to Promote AML
Drug Development
Recent Drug Approvals
Rising Investments in AML Therapeutics R&D Augurs Well
Need for Better Treatments Entrenches Proteomics at Center of
Acute Myeloid Leukaemia Therapeutics R&D
Antibody-Oriented Protein Microarrays
AML - A Medical Challenge with High Relapse Rate
Therapeutic Landscape for Refractory/Relapsed Acute Myeloid
Leukaemia
Advances Related to FLT3 Inhibitors
Gilteritinib to Set New Therapeutic Paradigm for Acute Myeloid
Leukaemia
Novel Combination Therapies for Relapsed or Refractory AML
Novel Therapies for Treatment of Pediatric Relapsed AML
Immunotherapy Research for AML
Monoclonal Antibody (Mylotarg) - A Promising Drug

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for Acute Myeloid
Leukaemia (AML) Therapeutics by Geographic Region - USA,
Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 2: World Historic Review for Acute Myeloid Leukaemia
(AML) Therapeutics by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2012 through 2019 and % CAGR

Table 3: World 15-Year Perspective for Acute Myeloid Leukaemia
(AML) Therapeutics by Geographic Region - Percentage Breakdown
of Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets for
Years 2012, 2021 & 2027

Table 4: World Current & Future Analysis for Cytarabine by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 5: World Historic Review for Cytarabine by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 6: World 15-Year Perspective for Cytarabine by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2021 & 2027

Table 7: World Current & Future Analysis for Anthracycline
Drugs by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 8: World Historic Review for Anthracycline Drugs by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 9: World 15-Year Perspective for Anthracycline Drugs by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027

Table 10: World Current & Future Analysis for Tyrosine Kinase
Inhibitors by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR

Table 11: World Historic Review for Tyrosine Kinase Inhibitors
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 12: World 15-Year Perspective for Tyrosine Kinase
Inhibitors by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2012, 2021 &
2027

Table 13: World Current & Future Analysis for Alkylating Agents
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 14: World Historic Review for Alkylating Agents by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 15: World 15-Year Perspective for Alkylating Agents by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027

Table 16: World Current & Future Analysis for Hormonal Therapy
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 17: World Historic Review for Hormonal Therapy by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 18: World 15-Year Perspective for Hormonal Therapy by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027

Table 19: World Current & Future Analysis for Anti-Metabolites
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 20: World Historic Review for Anti-Metabolites by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 21: World 15-Year Perspective for Anti-Metabolites by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027

Table 22: World Current & Future Analysis for Other
Chemotherapy Types by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2020 through 2027 and % CAGR

Table 23: World Historic Review for Other Chemotherapy Types by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 24: World 15-Year Perspective for Other Chemotherapy
Types by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2012, 2021 &
2027

III. MARKET ANALYSIS

UNITED STATES
Table 25: USA Current & Future Analysis for Acute Myeloid
Leukaemia (AML) Therapeutics by Chemotherapy Type - Cytarabine,
Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating
Agents, Hormonal Therapy, Anti-Metabolites and Other
Chemotherapy Types - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 26: USA Historic Review for Acute Myeloid Leukaemia (AML)
Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline
Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal
Therapy, Anti-Metabolites and Other Chemotherapy Types Markets -
Independent Analysis of Annual Sales in US$ Thousand for
Years 2012 through 2019 and % CAGR

Table 27: USA 15-Year Perspective for Acute Myeloid Leukaemia
(AML) Therapeutics by Chemotherapy Type - Percentage Breakdown
of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine
Kinase Inhibitors, Alkylating Agents, Hormonal Therapy,
Anti-Metabolites and Other Chemotherapy Types for the Years
2012, 2021 & 2027

CANADA
Table 28: Canada Current & Future Analysis for Acute Myeloid
Leukaemia (AML) Therapeutics by Chemotherapy Type - Cytarabine,
Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating
Agents, Hormonal Therapy, Anti-Metabolites and Other
Chemotherapy Types - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 29: Canada Historic Review for Acute Myeloid Leukaemia
(AML) Therapeutics by Chemotherapy Type - Cytarabine,
Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating
Agents, Hormonal Therapy, Anti-Metabolites and Other
Chemotherapy Types Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 30: Canada 15-Year Perspective for Acute Myeloid
Leukaemia (AML) Therapeutics by Chemotherapy Type - Percentage
Breakdown of Value Sales for Cytarabine, Anthracycline Drugs,
Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal
Therapy, Anti-Metabolites and Other Chemotherapy Types for the
Years 2012, 2021 & 2027

JAPAN
Table 31: Japan Current & Future Analysis for Acute Myeloid
Leukaemia (AML) Therapeutics by Chemotherapy Type - Cytarabine,
Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating
Agents, Hormonal Therapy, Anti-Metabolites and Other
Chemotherapy Types - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 32: Japan Historic Review for Acute Myeloid Leukaemia
(AML) Therapeutics by Chemotherapy Type - Cytarabine,
Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating
Agents, Hormonal Therapy, Anti-Metabolites and Other
Chemotherapy Types Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 33: Japan 15-Year Perspective for Acute Myeloid Leukaemia
(AML) Therapeutics by Chemotherapy Type - Percentage Breakdown
of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine
Kinase Inhibitors, Alkylating Agents, Hormonal Therapy,
Anti-Metabolites and Other Chemotherapy Types for the Years
2012, 2021 & 2027

CHINA
Table 34: China Current & Future Analysis for Acute Myeloid
Leukaemia (AML) Therapeutics by Chemotherapy Type - Cytarabine,
Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating
Agents, Hormonal Therapy, Anti-Metabolites and Other
Chemotherapy Types - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 35: China Historic Review for Acute Myeloid Leukaemia
(AML) Therapeutics by Chemotherapy Type - Cytarabine,
Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating
Agents, Hormonal Therapy, Anti-Metabolites and Other
Chemotherapy Types Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 36: China 15-Year Perspective for Acute Myeloid Leukaemia
(AML) Therapeutics by Chemotherapy Type - Percentage Breakdown
of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine
Kinase Inhibitors, Alkylating Agents, Hormonal Therapy,
Anti-Metabolites and Other Chemotherapy Types for the Years
2012, 2021 & 2027

EUROPE
Table 37: Europe Current & Future Analysis for Acute Myeloid
Leukaemia (AML) Therapeutics by Geographic Region - France,
Germany, Italy, UK, Spain, Russia and Rest of Europe Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 38: Europe Historic Review for Acute Myeloid Leukaemia
(AML) Therapeutics by Geographic Region - France, Germany,
Italy, UK, Spain, Russia and Rest of Europe Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 39: Europe 15-Year Perspective for Acute Myeloid
Leukaemia (AML) Therapeutics by Geographic Region - Percentage
Breakdown of Value Sales for France, Germany, Italy, UK, Spain,
Russia and Rest of Europe Markets for Years 2012, 2021 & 2027

Table 40: Europe Current & Future Analysis for Acute Myeloid
Leukaemia (AML) Therapeutics by Chemotherapy Type - Cytarabine,
Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating
Agents, Hormonal Therapy, Anti-Metabolites and Other
Chemotherapy Types - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 41: Europe Historic Review for Acute Myeloid Leukaemia
(AML) Therapeutics by Chemotherapy Type - Cytarabine,
Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating
Agents, Hormonal Therapy, Anti-Metabolites and Other
Chemotherapy Types Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 42: Europe 15-Year Perspective for Acute Myeloid
Leukaemia (AML) Therapeutics by Chemotherapy Type - Percentage
Breakdown of Value Sales for Cytarabine, Anthracycline Drugs,
Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal
Therapy, Anti-Metabolites and Other Chemotherapy Types for the
Years 2012, 2021 & 2027

FRANCE
Table 43: France Current & Future Analysis for Acute Myeloid
Leukaemia (AML) Therapeutics by Chemotherapy Type - Cytarabine,
Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating
Agents, Hormonal Therapy, Anti-Metabolites and Other
Chemotherapy Types - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 44: France Historic Review for Acute Myeloid Leukaemia
(AML) Therapeutics by Chemotherapy Type - Cytarabine,
Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating
Agents, Hormonal Therapy, Anti-Metabolites and Other
Chemotherapy Types Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 45: France 15-Year Perspective for Acute Myeloid
Leukaemia (AML) Therapeutics by Chemotherapy Type - Percentage
Breakdown of Value Sales for Cytarabine, Anthracycline Drugs,
Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal
Therapy, Anti-Metabolites and Other Chemotherapy Types for the
Years 2012, 2021 & 2027

GERMANY
Table 46: Germany Current & Future Analysis for Acute Myeloid
Leukaemia (AML) Therapeutics by Chemotherapy Type - Cytarabine,
Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating
Agents, Hormonal Therapy, Anti-Metabolites and Other
Chemotherapy Types - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 47: Germany Historic Review for Acute Myeloid Leukaemia
(AML) Therapeutics by Chemotherapy Type - Cytarabine,
Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating
Agents, Hormonal Therapy, Anti-Metabolites and Other
Chemotherapy Types Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 48: Germany 15-Year Perspective for Acute Myeloid
Leukaemia (AML) Therapeutics by Chemotherapy Type - Percentage
Breakdown of Value Sales for Cytarabine, Anthracycline Drugs,
Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal
Therapy, Anti-Metabolites and Other Chemotherapy Types for the
Years 2012, 2021 & 2027

ITALY
Table 49: Italy Current & Future Analysis for Acute Myeloid
Leukaemia (AML) Therapeutics by Chemotherapy Type - Cytarabine,
Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating
Agents, Hormonal Therapy, Anti-Metabolites and Other
Chemotherapy Types - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 50: Italy Historic Review for Acute Myeloid Leukaemia
(AML) Therapeutics by Chemotherapy Type - Cytarabine,
Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating
Agents, Hormonal Therapy, Anti-Metabolites and Other
Chemotherapy Types Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 51: Italy 15-Year Perspective for Acute Myeloid Leukaemia
(AML) Therapeutics by Chemotherapy Type - Percentage Breakdown
of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine
Kinase Inhibitors, Alkylating Agents, Hormonal Therapy,
Anti-Metabolites and Other Chemotherapy Types for the Years
2012, 2021 & 2027

UNITED KINGDOM
Table 52: UK Current & Future Analysis for Acute Myeloid
Leukaemia (AML) Therapeutics by Chemotherapy Type - Cytarabine,
Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating
Agents, Hormonal Therapy, Anti-Metabolites and Other
Chemotherapy Types - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 53: UK Historic Review for Acute Myeloid Leukaemia (AML)
Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline
Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal
Therapy, Anti-Metabolites and Other Chemotherapy Types Markets -
Independent Analysis of Annual Sales in US$ Thousand for
Years 2012 through 2019 and % CAGR

Table 54: UK 15-Year Perspective for Acute Myeloid Leukaemia
(AML) Therapeutics by Chemotherapy Type - Percentage Breakdown
of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine
Kinase Inhibitors, Alkylating Agents, Hormonal Therapy,
Anti-Metabolites and Other Chemotherapy Types for the Years
2012, 2021 & 2027

SPAIN
Table 55: Spain Current & Future Analysis for Acute Myeloid
Leukaemia (AML) Therapeutics by Chemotherapy Type - Cytarabine,
Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating
Agents, Hormonal Therapy, Anti-Metabolites and Other
Chemotherapy Types - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 56: Spain Historic Review for Acute Myeloid Leukaemia
(AML) Therapeutics by Chemotherapy Type - Cytarabine,
Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating
Agents, Hormonal Therapy, Anti-Metabolites and Other
Chemotherapy Types Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 57: Spain 15-Year Perspective for Acute Myeloid Leukaemia
(AML) Therapeutics by Chemotherapy Type - Percentage Breakdown
of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine
Kinase Inhibitors, Alkylating Agents, Hormonal Therapy,
Anti-Metabolites and Other Chemotherapy Types for the Years
2012, 2021 & 2027

RUSSIA
Table 58: Russia Current & Future Analysis for Acute Myeloid
Leukaemia (AML) Therapeutics by Chemotherapy Type - Cytarabine,
Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating
Agents, Hormonal Therapy, Anti-Metabolites and Other
Chemotherapy Types - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 59: Russia Historic Review for Acute Myeloid Leukaemia
(AML) Therapeutics by Chemotherapy Type - Cytarabine,
Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating
Agents, Hormonal Therapy, Anti-Metabolites and Other
Chemotherapy Types Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 60: Russia 15-Year Perspective for Acute Myeloid
Leukaemia (AML) Therapeutics by Chemotherapy Type - Percentage
Breakdown of Value Sales for Cytarabine, Anthracycline Drugs,
Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal
Therapy, Anti-Metabolites and Other Chemotherapy Types for the
Years 2012, 2021 & 2027

REST OF EUROPE
Table 61: Rest of Europe Current & Future Analysis for Acute
Myeloid Leukaemia (AML) Therapeutics by Chemotherapy Type -
Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors,
Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other
Chemotherapy Types - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 62: Rest of Europe Historic Review for Acute Myeloid
Leukaemia (AML) Therapeutics by Chemotherapy Type - Cytarabine,
Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating
Agents, Hormonal Therapy, Anti-Metabolites and Other
Chemotherapy Types Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 63: Rest of Europe 15-Year Perspective for Acute Myeloid
Leukaemia (AML) Therapeutics by Chemotherapy Type - Percentage
Breakdown of Value Sales for Cytarabine, Anthracycline Drugs,
Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal
Therapy, Anti-Metabolites and Other Chemotherapy Types for the
Years 2012, 2021 & 2027

ASIA-PACIFIC
Table 64: Asia-Pacific Current & Future Analysis for Acute
Myeloid Leukaemia (AML) Therapeutics by Geographic Region -
Australia, India, South Korea and Rest of Asia-Pacific Markets -
Independent Analysis of Annual Sales in US$ Thousand for
Years 2020 through 2027 and % CAGR

Table 65: Asia-Pacific Historic Review for Acute Myeloid
Leukaemia (AML) Therapeutics by Geographic Region - Australia,
India, South Korea and Rest of Asia-Pacific Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 66: Asia-Pacific 15-Year Perspective for Acute Myeloid
Leukaemia (AML) Therapeutics by Geographic Region - Percentage
Breakdown of Value Sales for Australia, India, South Korea and
Rest of Asia-Pacific Markets for Years 2012, 2021 & 2027

Table 67: Asia-Pacific Current & Future Analysis for Acute
Myeloid Leukaemia (AML) Therapeutics by Chemotherapy Type -
Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors,
Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other
Chemotherapy Types - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 68: Asia-Pacific Historic Review for Acute Myeloid
Leukaemia (AML) Therapeutics by Chemotherapy Type - Cytarabine,
Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating
Agents, Hormonal Therapy, Anti-Metabolites and Other
Chemotherapy Types Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 69: Asia-Pacific 15-Year Perspective for Acute Myeloid
Leukaemia (AML) Therapeutics by Chemotherapy Type - Percentage
Breakdown of Value Sales for Cytarabine, Anthracycline Drugs,
Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal
Therapy, Anti-Metabolites and Other Chemotherapy Types for the
Years 2012, 2021 & 2027

AUSTRALIA
Table 70: Australia Current & Future Analysis for Acute Myeloid
Leukaemia (AML) Therapeutics by Chemotherapy Type - Cytarabine,
Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating
Agents, Hormonal Therapy, Anti-Metabolites and Other
Chemotherapy Types - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 71: Australia Historic Review for Acute Myeloid Leukaemia
(AML) Therapeutics by Chemotherapy Type - Cytarabine,
Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating
Agents, Hormonal Therapy, Anti-Metabolites and Other
Chemotherapy Types Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 72: Australia 15-Year Perspective for Acute Myeloid
Leukaemia (AML) Therapeutics by Chemotherapy Type - Percentage
Breakdown of Value Sales for Cytarabine, Anthracycline Drugs,
Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal
Therapy, Anti-Metabolites and Other Chemotherapy Types for the
Years 2012, 2021 & 2027

INDIA
Table 73: India Current & Future Analysis for Acute Myeloid
Leukaemia (AML) Therapeutics by Chemotherapy Type - Cytarabine,
Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating
Agents, Hormonal Therapy, Anti-Metabolites and Other
Chemotherapy Types - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 74: India Historic Review for Acute Myeloid Leukaemia
(AML) Therapeutics by Chemotherapy Type - Cytarabine,
Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating
Agents, Hormonal Therapy, Anti-Metabolites and Other
Chemotherapy Types Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 75: India 15-Year Perspective for Acute Myeloid Leukaemia
(AML) Therapeutics by Chemotherapy Type - Percentage Breakdown
of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine
Kinase Inhibitors, Alkylating Agents, Hormonal Therapy,
Anti-Metabolites and Other Chemotherapy Types for the Years
2012, 2021 & 2027

SOUTH KOREA
Table 76: South Korea Current & Future Analysis for Acute
Myeloid Leukaemia (AML) Therapeutics by Chemotherapy Type -
Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors,
Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other
Chemotherapy Types - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 77: South Korea Historic Review for Acute Myeloid
Leukaemia (AML) Therapeutics by Chemotherapy Type - Cytarabine,
Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating
Agents, Hormonal Therapy, Anti-Metabolites and Other
Chemotherapy Types Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 78: South Korea 15-Year Perspective for Acute Myeloid
Leukaemia (AML) Therapeutics by Chemotherapy Type - Percentage
Breakdown of Value Sales for Cytarabine, Anthracycline Drugs,
Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal
Therapy, Anti-Metabolites and Other Chemotherapy Types for the
Years 2012, 2021 & 2027

REST OF ASIA-PACIFIC
Table 79: Rest of Asia-Pacific Current & Future Analysis for
Acute Myeloid Leukaemia (AML) Therapeutics by Chemotherapy Type -
Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors,
Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other
Chemotherapy Types - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 80: Rest of Asia-Pacific Historic Review for Acute
Myeloid Leukaemia (AML) Therapeutics by Chemotherapy Type -
Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors,
Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other
Chemotherapy Types Markets - Independent Analysis of Annual

Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p06051402/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001